Le Centre de Neurosciences Psychiatriques et le Service d’alcoologie

ANNOUNCEMENT

Friday, September 13, 2013, 9:30am

“Gabapentin as a Novel Treatment for Alcohol and Cannabis Dependence”

Barbara J Mason PhD
Pearson Family Professor, Committee on the Neurobiology of Addictive Disorders
Director, Laboratory of Clinical Psychopharmacology
Co-Director, Pearson Center for Alcoholism and Addiction Research
The Scripps Research Institute

Invited by Prof. Jean-Bernard Daeppen and Dr. Benjamin Boutrel
(Jean-Bernard.Daeppen@chuv.ch)
(Benjamin.Boutrel@chuv.ch)

Salle Andros (PMU 08)
Rue du Bugnon 44
1011 Lausanne

Based on positive findings in pre-clinical and human laboratory models of alcohol dependence, a series of randomized controlled trials were conducted in outpatients with cannabis dependence or alcohol dependence. For both substance use disorders, gabapentin was associated with significant reductions in substance use, craving, and substance-related disturbances in sleep and mood, with a favorable safety profile.

References:
